Yun Fan

2 weeks ago | nature.com | Ying Cheng |Jun Liao |Jordi Rodon |Yongsheng Li |Yun Fan |Jin Billy Li | +1 more

AbstractTrophoblast cell-surface antigen 2 (TROP2)-directed antibody–drug conjugate (ADC) is a promising anticancer agent that has shown remarkable efficacy in several malignancies. However, in lung cancer, two phase 3 trials on TROP2-ADCs in unselected patients with advanced non-small-cell lung cancer (NSCLC) have both failed. Sacituzumab tirumotecan (sac-TMT) is a novel TROP2-directed ADC.

1 month ago | nature.com | Yuxiang Ma |Yun Fan |Siqing Fu |Lin Wu |David Sommerhalder |Wei Lian | +2 more

AbstractAntibody–drug conjugates (ADCs) have emerged as a transformative modality in the treatment of solid tumors. YL201, a novel B7H3-targeting ADC, leverages a tumor microenvironment activable linker-payload platform, coupled with a novel topoisomerase 1 inhibitor via a protease-cleavable linker.